07:24 AM EDT, 06/11/2024 (MT Newswires) -- Viridian Therapeutics ( VRDN ) said Tuesday that it will begin two late-stage clinical trials to evaluate VRDN-003 in patients with active and chronic thyroid eye disease in August.

The trials will assess two active dosing regimens of VRDN-003, both with a primary endpoint of proptosis responder rate compared with placebo, said Viridian Therapeutics ( VRDN ). Topline data from the trials are expected in the first half of 2026, with the company aiming to file a biologics license application for VRDN-003 by the end of 2026.

Shares of Viridian Therapeutics ( VRDN ) were up more than 12% in recent Tuesday premarket activity.

Price: 13.76, Change: +1.54, Percent Change: +12.60